Purpose. We aimed to establish the prevalence of different Burkholderia species among UK cystic fibrosis (CF) and non-CF patients over a 2 year period.
INTRODUCTION
The genus Burkholderia encompasses species with wideranging plant, human and animal pathogenesis and symbioses. Those of particular clinical relevance include Burkholderia pseudomallei, the pathogen responsible for melioidosis, Burkholderia mallei which causes glanders in horses, and species of the Burkholderia cepacia complex (Bcc) and Burkholderia gladioli which colonize and infect immune-compromised patients, including those with cystic fibrosis (CF). The Bcc currently comprises 20 closely related species [1] [2] [3] [4] [5] [6] . Originally identified by Burkholder in 1940 as a cause of onion rot, the Bcc has the capacity for beneficial interactions with plant hosts and it may be useful in bioremediation and as a plant-growth enhancer, due in part to its synthesis of anti-fungal agents [7] [8] [9] . For CF patients, the Bcc is responsible for increased morbidity and mortality, reduced lung function and causing pro-inflammatory damage [10] . In recent years its role as a nosocomial pathogen and as a contaminant of medical equipment and products such as ultrasound gel and chlorhexidine wipes has also been increasingly documented [11] [12] [13] .
In the USA and Canada, Burkholderia multivorans is currently the most prevalent Bcc species among CF patients, followed by Burkholderia cenocepacia [14, 15] , where previously the latter species was more frequently isolated [16] . The higher prevalence of these two species among CF patients has also been reported in New Zealand and Australia [17, 18] , and in several European countries [19] [20] [21] [22] . The last large UK study of Bcc prevalence was published over a decade ago [23] prior to the classification of many of the newer species, and utilized species-species recA PCR analysis for which cross-reactions between the original and newer species of the Bcc are now known to occur.
Other species of the genus Burkholderia such as B. gladioli have been less commonly reported among UK CF patients, but are estimated to be more common in the USA, where approximately 15 % of CF patients harbour this species [15] . There have been several reports of poor outcome for B. gladioli-infected CF patients post-lung transplant [24] [25] [26] .
As the UK reference laboratory, we routinely receive isolates from UK hospitals for identification and cross-infection investigations. We offer species-level identification for isolates of the Bcc, which is performed by recA gene sequence clustering. We also routinely confirm the identification of other species of the genus Burkholderia such as B. gladioli and B. pseudomallei. In 2010, the CF Trust consensus document 'Laboratory standards for processing microbiological samples from people with cystic fibrosis' [27] stipulated that recA sequencing should be the recommended method for species-level identification within the Bcc and, to the best of our knowledge, the majority of UK hospital laboratories submit CF Burkholderia spp. isolates to our laboratory for this purpose. The aim of this study was to review the UK prevalence of different Burkholderia species among CF patients received over a 2 year period from March 2013 to March 2015, while also estimating the prevalence of those derived from non-CF and hospital environmental sources. We also wished to characterize common circulating strains by multi-locus-sequence typing (MLST) to obtain a context for wider international clonal prevalence. UK CF Trust Registry data were sought to examine the clinical impact of different Bcc species on CF patients' health using lung function parameters (FEV1 % predicted) and intravenous (IV) antibiotic requirement, and to assess whether the prevalence data from our laboratory accurately reflected UK CF Bcc infection rates.
METHODS

Isolate source
Isolates were submitted for confirmation of identification from 79 hospitals. Submissions from 361 CF patients comprised 800 isolates from sputum, 61 cough swabs, nine from bronchoalveolar lavage (BAL), three throat swabs, three bronchial washings and one nasal secretion isolate. Submissions from 112 non-CF patients comprised 48 blood isolates, 44 from sputum, eight from urine, five from BAL, three from central venous catheter sites, three joint fluid swabs, two each from pleural fluid, rectal swabs, peritoneal dialysis fluid, wound swabs and bronchial washings, and single isolates from ascitic fluid, bronchial aspirate, line tip, pus, skin, vitreous fluid and tracheal aspirate. No information was provided for 11 CF and four non-CF isolates.
Identification by matrix-assisted laser-desorption/ ionization time-of-flight mass spectrometry (MALDI-TOF MS) Isolates were cultured aerobically overnight at 37 C on nutrient agar. Preliminary identification to genus level was conducted using MALDI-TOF MS, following ethanol and formic acid extraction on a Bruker Microflex instrument (Bruker). Isolates were tested in duplicate and provisionally classified to genus and species level using the 'MALDI Biotyper Realtime classification' program using Bruker's Security-Relevant database.
Species-level identification within the genus Burkholderia and MLST Primers used for Burkholderia species-level identification in this study are detailed in Table S1 (available in the online Supplementary Material). Briefly, for identification of the Bcc, BCR1/2 primers [1] were used in conjunction with mpcableF148/mpcableR419 primers [28] , the latter to detect the presence of the cable pilus. Four sequencing reactions (with BCR1, BCR2, BCC SeqF1 and BCC SeqR2) were used to ensure adequate recA gene coverage. For B. gladioli identification, gyrB primers PAR gyrB F/R were used with additional sequencing primers PC2 and PC3. Primers BpTT4176F and BpTT4290R [29] were used for the identification of B. pseudomallei, and genus Burkholderia primers BUR1/2 for the sequencing of Burkholderia tropica [30] . For all PCR reactions crude DNA extracts were prepared by suspending a few colonies of bacterial growth in 100 µl of PCRgrade water, vortexing and centrifuging at 21 130 g for 2 min, except for B. pseudomallei, for which a small loopful of cells was suspended in 500 µl PCR-grade water before undergoing heat-killing in a steamer at 95 C for 15 min prior to removal from containment level 3. PCR reactions were carried out in a PTC-225 Peltier Themal Cycler DNA Engine Tetrad (MJ Research) using QIAGEN Core kit reagents in 25 µl volumes containing 1Â PCR buffer (containing 1.5 mM MgCl 2 ), an additional 1.5 mM MgCl 2 , 1Â Q solution, 250 µM of each deoxynucleoside triphosphate, 1.5 U Taq DNA polymerase, 10 pmol of each primer and 3 µl crude DNA extract. Thermal cycler conditions for the Bcc recA PCR were as described previously [28] . For gyrB amplification, conditions were as follows: Pulsed-field gel electrophoresis (PFGE) PFGE was conducted following restriction with XbaI as described previously [35] . BioNumerics 6.1 (Applied Maths) was used to calculate percentage similarity using the Dice coefficient, with isolates clustered by unweighted pair-group method with arithmetic mean (UPGMA).
UK CF Trust Registry data UK CF Trust Registry information was sought for patients recorded as harbouring species of the Burkholderia genus. Two parameters were examined. The first was patients' requirement for in-patient and/or home IV antibiotics and the second, patients' FEV1 % predicted, which is the forced expiratory volume in one second divided by the average FEV1 % in the population for any person of similar age, sex and body composition. These parameters were examined among patients harbouring B. cenocepacia, B. multivorans and those harbouring 'other Bcc' species. X 2 tests were used to test for associations, supplemented by Fisher exact tests where numbers were small. Bonferroni adjustments were applied to post hoc comparisons. Statistical analyses were conducted using SAS/STAT software, version 9.3 of the SAS System for Windows (SAS Institute, 2012).
RESULTS AND DISCUSSION
MALDI-TOF identification
All Burkholderia isolates, apart from those suspected and subsequently confirmed as B. pseudomallei, underwent initial analysis by MALDI-TOF. Bruker's restriction information states that MALDI-TOF cannot reliably separate species of the Bcc. In this study we classified reliable identification as a score of !2.3 after ethanol and formic acid extraction, with confirmation by recA sequence cluster analysis. For some examples, such as B. multivorans, species-level identification by MALDI-TOF fell within these parameters for 89 % of isolates, with only one false-positive identification for B. pseudomultivorans (score below 2.2) among more than 400 isolates screened. A high percentage (88 and 85 %, respectively) of B. cenocepacia IIIA and IIIB isolates were also correctly identified, although MALDI-TOF is unable to differentiate between these subgroups. B. vietnamiensis was correctly identified in 86 % of isolates (67) screened, whereas B. cepacia was the least accurately identified species with a correct identification and score of !2.3 recorded for only 72 % of isolates. Significant, but unsurprising incorrect identifications occurred with novel species, which were not present in Bruker's database. Two isolates of Burkholderia territorii were misidentified as B. cenocepacia with scores of 2.3. Ten isolates of the novel cluster represented by BCCU7 (GenBank accession number EU475901), from a single patient, were variably identified as B. cepacia, Burkholderia diffusa, B. cenocepacia and B. vietnamiensis, on two occasions with scores of 2.3. Misidentification of novel species as known species of the Bcc, especially B. cenocepacia, may have serious implications for hospitals that rely on MALDI-TOF for Bcc species confirmation, particularly for isolates from CF patients, where incorrect Bcc assignment may preclude these patients from lung transplant.
MALDI-TOF correctly identified all 39 isolates of B. gladioli, although 49 % of these had scores of less than 2.3, with a range of 2.02-2.21.
Genus Burkholderia prevalence in CF and non-CF patients recA sequence clustering of Bcc isolates received from 334 UK CF patients (and nine from the Republic of Ireland; therefore a total of 343) over the 2 year study period revealed that the majority (192; 56 %) harboured B. multivorans, with the next most prevalent species being B. cenocepacia (IIIA 52, 15 % and IIIB 30, 9 %). B. vietnamiensis shared equal prevalence with B. cenocepacia IIIB among these patients (31 patients, 9 %) ( Table 1 ). These data are in agreement with other studies from Europe, USA, Australia and New Zealand over the past decade in finding these are the two most common species among this group of patients Not tested. *NCF, Non-CF. †No differentiation between B. cenocepacia IIIA and IIIB. recA GenBank accession numbers for previously described recA sequences BCCU3: EF408667, BCCU6: EU475900, BCCU7: EU475901 [28] , and from this study BCCUG8: KY077296, BCCUG9: KY077297, BCCU10: KY077298, BCCUG11: KY077299, BCCUG12; KY077300. BCCUG13 did not produce a recA PCR amplicon with primers BCR1 and 2.
[ [16] [17] [18] [19] [20] [21] 36] . The dominance of B. multivorans among UK CF patients highlighted by our group in 2007 is even clearer in this larger patient group [28] .
Isolates from two patients clustered with previously described isolates with novel recA sequences (BCCU3; GenBank accession number EF408667 and BCCU7; EU475901, respectively) [28] . Three additional putative novel species (referred to as BCCUG9, BCCUG10 and BCCUG11; GenBank accession numbers KY077297, KY077298 and KY077299, respectively) were identified, representatives of which clustered with less than 99 % similarity with any previously described type and reference strains (Fig. 1) . Two isolates (BCCUG8 and BCCUG12; accession numbers KY077296 and KY077300) had relatively small differences (five and three base differences, respectively, over 897 bp of recA sequence) from representatives of Burkholderia stabilis, but as this species is notoriously stable, these have also been designated putative novel species. Seven non-CF patients
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Burkholderia Dendrogram showing comparison of an 897 bp section of the recA gene from putative novel species BCCUG8-12 and previously described putative novel species BCCU7 and BCCU3, compared with current type and reference strains of the B. cepacia complex. The evolutionary history was inferred using the neighbour-joining method [52] . The optimal tree with the sum of branch lengths=0.472 is shown. The percentages of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches [53] . The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the maximum composite likelihood method [54] and are in the units of the number of base substitutions per site. Evolutionary analyses were conducted in MEGA6 [55] . harboured BCCUG8, while BCCUG9 was isolated from three isolates from a cosmetic product submitted from a commercial company. Single CF patient isolates of BCCUG10 and BCCUG11 were also received. The previously described recA sequence BCCU6 (GenBank accession number EU475900) isolated from one CF patient has been re-assigned to the recently described B. territorii species [6] . BCCUG12 was a single isolate from one CF patient, while a further novel group (BCCUG13) comprised two isolates from a further CF patient that did not amplify using the recA BCR1 and two primers, but did produce an amplicon with both the genus Burkholderia and gyrB primers, neither of which matched any of the Bcc type strain sequences on GenBank.
A single isolation of B. tropica was identified in one paediatric CF patient. Initial identification with a score of 2.4 by MALDI-TOF was confirmed by recA sequencing using genus Burkholderia primers [30] . This organism has previously only been documented in human infection associated with an immunocompromised neonate in Malaysia [37] , and as a plant pathogen from temperate sub-humid and tropical humid climates such as South America and Mexico [38] . This patient had no history of travel so it was not clear how this organism was acquired.
B. pseudomallei was isolated from one CF patient with a history of travel to Cambodia and Vietnam where this organism is endemic. This patient had been chronically infected with this pathogen over a period of 5 years [39] . This organism was also isolated from seven non-CF patients in this 2 year period (four blood isolates, one isolate from a skin ulcer and one isolate each from bone and a prostatic abscess). All but one of these patients had recently travelled to endemic countries; the other patient was visiting the UK from India. All B. pseudomallei isolates were resistant in vitro to ciprofloxacin (MIC>1 mg l À1 ), with the two CF patient isolates additionally resistant to co-trimoxazole (MIC>32 mg l À1 ).
B. gladioli was identified in 16 CF patients, suggesting a much lower prevalence of infection than has been reported in the USA (15 %). Also in contrast to studies in the USA and France where 60 and 61.5 % of CF infections were transient, three of four CF patients whose isolates underwent PFGE have harboured their strains for at least between 2 and 9 years.
Non-CF referrals were likely to be an underestimate of Burkholderia spp. nosocomial infections, particularly since the introduction of MALDI-TOF in many diagnostic laboratories. Of the 112 non-CF patients, B. cepacia was the most common species received (40 isolates from 37 patients). Analysis by PFGE revealed that 18 of these isolates from 16 hospitals represented a single strain. The second most common species received from non-CF patients was B. cenocepacia IIIA (30 isolates from 25 patients). The Bcc isolated from non-CF patients were isolated from a wide range of hospital wards and other sources (21 intensive therapy unit (ITU) patients, eight accident and emergency, one acute admission, five from general wards, seven from cardiac units, two GP patients, five from neonatal/paediatric ITU, one from general paediatrics, one from paediatric neurology, one from an infectious diseases ward, eight critical care patients, three from out-patient departments and eight associated with renal procedures). On 34 request forms no ward information was provided. Burkholderia fungorum was isolated from two non-CF patients during the study period.
Antibiotic susceptibility testing of the Bcc EUCAST state that it is currently not possible to recommend susceptibility testing of Burkholderia spp. to guide patient therapy [40] . However, we have used the best available MIC breakpoints as guidance for clinicians. Table 2 shows the MICs of nine antibiotics determined for B. cepacia (consisting of seven CF; 11 non-CF isolates), B. multivorans (75 CF; 14 non-CF isolates); B. cenocepacia IIIA (14 CF; 10 non-CF isolates) and IIIB (12 CF; four non-CF isolates), B. contaminans (three CF; two non-CF isolates) and B. vietnamiensis (eight CF; one non-CF isolate) interpreted according to CLSI breakpoint guidelines. Nevertheless, MICs have to be read with the proviso that susceptibility may change in vivo and that interpretations of susceptibility may not be accurate on a Pharmacokinetic/ Pharmacodynamic (PK/PD) basis for individual treatment. In addition, it is difficult to assess differences in resistance rates between non-CF and CF isolates accurately due to the disparity in numbers, and likewise to assess intra-species differences. Controversially, the nine B. vietnamiensis isolates tested were unusually susceptible to all of the antibiotics tested, which contrasted with a high proportion (86 %, 12 isolates) of B. cenocepacia IIIA CF isolates resistant to amikacin, and 83 % (10 isolates) of B. cenocepacia IIIB CF isolates. Resistance to aztreonam was also high for B. cepacia CF isolates (86 %; six isolates); and likewise for imipenem 86 % (six isolates). Eighty-six percent (65 isolates) of B. multivorans CF isolates were also imipenem-resistant. Meropenem resistance was low among CF isolates tested, apart from B. cepacia, as found in a recent study of Swiss CF isolates [19] . Resistance to ciprofloxacin, ceftazidime, co-trimoxazole, minocycline and piperacillin-tazobactam was variable across the species. Numbers of non-CF isolates tested were low, but imipenem resistance was high among B. cenocepacia IIIA isolates from non-CF patients (90 %, nine isolates) as was resistance among non-CF isolates of this species to amikacin (90 %, nine isolates).
Bcc shared strains and cross-infection
Well-characterized transmissible strains of the Bcc, such as the ET12 lineage of B. cenocepacia IIIA, have been responsible for increased mortality in CF patients due to their capacity to cause fulminating, often fatal, pneumonia and septicaemia (cepacia syndrome). Other prominent strains include the PHDC and Mid-West clones of B. cenocepacia IIIB in the USA, and ST39 from Australia [15, 41] . The introduction of strict infection prevention and control measures within CF clinics has resulted in a decline in the incidence of many of these strains over the past decade [15] . In this study, PFGE was used to estimate the proportion of shared strains among 343 isolates from 73 hospitals, of which 264 were from 194 CF patients.
Among CF patients, shared strains were mainly found between siblings. Two sibling pairs shared the same B. multivorans strain, two the same B. cenocepacia IIIA strain (one of which was shared between three siblings and with a fourth, unrelated patient), one sibling pair shared the same B. cenocepacia IIIB strain and one the same B. gladioli strain. Within seven of the larger clinics between six and 23 isolates were analysed in this period. In one of these hospitals there was one B. multivorans strain shared between four adult patients. Extension of the examination period for this clinic from 2012 to 2016 revealed one additional strain of B. cenocepacia IIIB shared between two patients, and a cable pili-negative B. cenocepacia strain shared between three adults. Aside from this clinic, and common strains shared between siblings, the few examples of shared strains in this study suggest that existing cross-infection measures for the Bcc are largely effective.
Four 'clusters' of highly related strains were found among the isolates detected by PFGE during this period (Fig. 2) . The first was a strain of B. cenocepacia IIIB, which was shared between five patients from the same hospital, although these were separated in time, with the first case outside the study period (2010) and the most recent in 2015. This strain type was also harboured by seven other CF patients from six other hospitals separated in time and space, suggesting that it is likely to be a successful clone (Fig. 2) . It belonged to ST1062, a sequence type for which there is currently only one other entry on the MLST database (http://pubmlst.org/bcc/), from a Belgian CF patient.
A second 'B. cenocepacia IIIB cluster' comprised six isolates from six adult CF patients from three UK hospitals. This strain type belonged to the ST125 clonal complex, examples of which have been submitted from both environmental and CF sources on the MLST database.
A small third 'cluster' consisted of one B. multivorans strain common to four patients (two CF and two non-CF patients) from four geographically distant hospitals. On MLST analysis this was found to be ST742, for which there was one entry on the MLST database, again derived from a CF patient in Belgium. The existence of these clusters suggests there may be a trend towards some patients acquiring successful clonal lineages, as has been noted for other pathogens such as P. aeruginosa [42] .
The fourth 'cluster' consisted of isolates of a strain of B. cepacia seen almost exclusively among non-CF patients (Fig. 2) . During the study period, 18 isolates of this strain were received from 16 hospitals, although this outbreak extended back to 2010 and, as of August 2016, included 79 isolates from 78 patients from 48 UK hospitals and two hospitals in the Republic of Ireland (comprising the following isolates: 45 blood, 14 sputum, two BAL, one tracheal aspirate, three wound, three pleural fluid, one cerebrospinal fluid, one seminal fluid, two ascites, one peritoneal swab, A common strain isolated from hospitals across the UK and Ireland suggested the possibility of a widely used contaminated medical product. Nosocomial Bcc outbreaks associated with contaminated medical products such as ultrasound gel, chlorhexidine, betadine/iodine skin disinfectant and moisturizing body washes have been described previously, however not to our knowledge over such an extended period of time [11, 43] . Between December 2010 and June 2011 questionnaires were submitted to 12 affected hospitals, but no clear hypothesis for a possible common source could be established. Several products were common in the care of the affected patients, the most common being chlorhexidine-based disinfectant wipes which might reflect widespread use rather than association with infection. In the majority of patients the strain was not thought to cause a clinically significant infection. It was also not possible to establish whether the infection had contributed to the deaths of two patients.
An investigation into another possible B. cepacia outbreak on a cardiac ward revealed that the four patient isolates represented two strains (one of which was ST767). Three additional strains were found among 16 ward environmental isolates, which also included four isolates of B. vietnamiensis. These data suggest that although the hospital environment was not responsible for these patient infections, it may be a possible source of infection in some instances.
Prevalence of cable pili-positive Bcc isolates
Usually associated with the ET12 lineage, the cable pilus is a well-established virulence factor associated with increased binding to epithelial cells, persistence and an increased proinflammatory response [10, 44] . The prevalence of cable pili-positive non-ET12 B. cenocepacia IIIA isolates was reexamined since first described by our group in 2009 [45] . The CF patients harbouring strains A and B described in the original publication continue to harbour these strains. Another paediatric CF patient with shared care at the hospital of the patient harbouring strain A harboured B. It is noteworthy that both the CF registry and our reference laboratory estimates of Bcc infections correlate with respect to numbers of patients harbouring the Bcc (326 in 2013 from the CF Registry, and isolates from 334 patients submitted to our laboratory in the 2 year period of this study). Likewise, the numbers of patients harbouring B. multivorans (163 for 2013 from the registry and 192 submitted to us) are broadly similar. The other members of the Bcc are not defined to species and subspecies level in the Registry data and so it is not possible to compare these data.
Data for 2014 were incomplete for one of the parameters we wished to use as a measure of patient health (IV antibiotic use) therefore only the 2013 data were used for further analysis. A X 2 test showed that there was no significant difference in lung function (FEV1 % predicted) between patients harbouring B. cenocepacia, B. multivorans and other Bcc species (P=0.81) in this year (Table 3) .
Post hoc tests using a Bonferroni correction to control for false positive error rates showed no significant differences between numbers of patients harbouring B. multivorans (31 %) and those harbouring B. cenocepacia (28 %) (P=0.17) across treatment categories. In contrast, there were significant differences between numbers for B. multivorans and the Bcc 'other' group (P=0.005), whereas differences between B. cenocepacia and Bcc 'other' were found to be borderline significant (P=0.025) ( Table 4) .
The proportion of patients with !50 days hospital and/or home IV antibiotic requirement was also examined. A X 2 test showed that there were no significant differences between the three patient groups (P=0.86), with 36 B. multivorans patients (22 %), 21 (21 %) B. cenocepacia patients and 10 (19 %) from the Bcc 'other' group falling within this category.
These data are unexpected given that historically it has been thought that CF patients harbouring B. cenocepacia have a poorer outcome than those patients harbouring B. multivorans [49] . Other than one description of poor outcome for [14, 50, 51] . This aspect of our study does not account for co-morbidities, co-infections or other aspects affecting CF patient health, but this 2013 snapshot suggests that a more in-depth study of CF Registry data is warranted to examine other risk factors, such as female gender outlined in the study by Zlosnik et al. [14] .
In conclusion, our study has shown the dominance of the Bcc over other species of the Burkholderia genus among UK patients and has highlighted the continued dominance of B. multivorans among UK CF patients, reflecting a wider global trend. New acquisitions of strains traditionally associated with transmissibility, such as the ET12 lineage of B. cenocepacia IIIA, among these patients were rare and evidence of cross-infection (apart from siblings) within CF clinics was relatively limited, suggesting that current segregation measures are largely successful. Examination of UK CF Trust Registry data found no significant difference in lung function (FEV1 % predicted) between patients harbouring B. cenocepacia, B. multivorans and other Bcc species (P=0.81) in 2013. Four 'clusters' of previously described sequence types were found among small numbers of CF and non-CF patients, but without epidemiological links suggesting some lineages may have a selective advantage over others, or are more widespread. The large number of B. cepacia ST767 isolates received from multiple centres in the UK and Republic of Ireland over 6 years highlights the adaptability and persistence of species within the Burkholderia genus.
